In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2011

A look at financing, M&A, and alliance activity July–September 2011

Executive Summary

Medical device companies raised a total of $906 million in Q3, while in vitro diagnostic/research developers took in $72 million. The top M&As in each segment were private buyouts of public companies: Kinetic Concepts for $6.3 billion and Immucor for $1.9 billion.

Advertisement

Related Content

Medtech in Ireland -- Turning Green into Gold
Ireland's Medtech Explosion
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
ConvaTec Makes Competing Bid For Wound Care Company Kinetic Concepts
Roche Broadens Cervical Cancer Testing Lineup With MTM Acquisition
Kinetic Concepts To Go Private Via $6.3 Billion Buyout
Medtronic Builds Surgical Device Offerings Via Salient, Peak Acquisitions
Immucor Accepts $2 Billion Private Equity Buyout, But Open To Richer Offer
Can Nanotech Be a Game-Changer for In Vitro Diagnostics?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel